Solvonis Therapeutics plc
SVNS.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £250 | £213 | £338 | £598 |
| - Cash | £1,719 | £757 | £27 | £155 |
| + Debt | £77 | £0 | £264 | £34 |
| Enterprise Value | -£1,392 | -£544 | £575 | £477 |
| Revenue | – | £0 | £0 | £347 |
| % Growth | – | – | -100% | – |
| Gross Profit | – | £0 | -£18 | £30 |
| % Margin | – | – | – | 8.6% |
| EBITDA | – | -£349 | -£348 | -£1,919 |
| % Margin | – | – | – | -553% |
| Net Income | – | -£335 | -£626 | -£1,994 |
| % Margin | – | – | – | -574.6% |
| EPS Diluted | – | -0.003 | -0.005 | -0.019 |
| % Growth | – | 46% | 74% | – |
| Operating Cash Flow | – | -£149 | -£423 | -£345 |
| Capital Expenditures | – | £0 | -£4 | £21 |
| Free Cash Flow | – | -£149 | -£427 | -£324 |